-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Definium Therapeutics, Raises Price Target to $79

Benzinga·09/15/2026 12:50:20
Listen to the news
Baird analyst Christopher Chen maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $75 to $79.